Paraneoplastic syndromes of the nervous system

Cancer Neurology In Clinical Practice: Neurologic Complications of Cancer and Its Treatment: Second Edition

Volumn , Issue , 2008, Pages 237-255

  Rosenfeld, Myrna R ^a   Dalmau, Josep ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cancers; cerebellar degeneration; neuropathy; paraneoplastic syndrome

Indexed keywords

EID: 84891470406     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-412-4_15     Document Type: Chapter

References (150)

1. Posner JB. Neurologic Complications of Cancer. Philadelphia: F.A.Davis, 1995.
2. Dalmau J, Graus F, Villarejo A et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127:1831-1844.
3. Vernino S, O'Neill BP, Marks RS et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neurooncol 2004; 6:55-62.
4. Bataller L, Kleopa KA, Wu GF et al. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry, 2007;78:381-5.
5. Bataller L, Dalmau JO. Paraneoplastic disorders of the central nervous system: update on diagnostic criteria and treatment. Semin Neurol 2004; 24:461-471.
6. Mathew RM, Cohen AB, Galetta SL et al. Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET. J Neurol Sci 2006; 250:153-155.
7. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349:1543-1554.
8. Rousseau A, Benyahia B, Dalmau J et al. T-cell response to Hu-D peptides in patients with anti-Hu syndrome. J Neurooncol 2005; 71:231-236.
9. Ances BM, Vitaliani R, Taylor RA et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 2005; 128:1764-1777.
10. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325:1487-1498.
11. Graus F, Delattre JY, Antoine JC et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75:1135-1140.
12. Dalmau J, Ttizun E, Wu H-Y et al. Paraneoplastic anti-NMDA receptor encephalitis associated with ovarian teratoma. Ann Neurol, 2007;6:25-36.
13. Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 2001; 21:173-187.
14. Dalmau J, Rosenfeld MR. Paraneoplastic neurologic syndromes. In: Kasper DL, Braunwald E, Fauci AS et al. (eds.). Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 2005:571-575.
15. Antoine JC, Honnorat J, Camdessanche JP et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001; 49:214-221.
16. Kuntzer T, Antoine JC, Steck AJ. Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies). Muscle Nerve 2004; 30:255-268.
17. Younes-Mhenni S, Janier MF, Cinotti L et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004; 127:2331-2338.
18. Rees JH, Hain SF, Johnson MR et al. The role of [18F]fluoro-2- deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 2001; 124:2223-2231.
19. Mathew RM, Vandenberghe R, Garcia-Merino A et al. Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. Neurology, 2007;68:900-5.
20. Vitaliani R, Mason W, Ances B et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005; 58:594-604.
21. Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N Engl J Med 1998; 338:1601-1607.
22. Gultekin SH, Rosenfeld MR, Voltz R et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000; 123:1481-1494.
23. Lawn ND, Westmoreland BF, Kiely MJ et al. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc 2003; 78:1363-1368.
24. Corsellis JA, Goldberg GJ, Norton AR. "Limbic encephalitis" and its association with carcinoma. Brain 1968; 91:481-496.
25. Stein-Wexler R, Wootton-Gorges SL, Greco CM et al. Paraneoplastic limbic encephalitis in a teenage girl with an immature ovarian teratoma. Pediatr Radiol 2005; 35:694-697.
26. Alamowitch S, Graus F, Uchuya M et al. Limbic encephalitis and small cell lung cancer: clinical and immunological features. Brain 1997; 120:923-928.
27. Pozo-Rosich P, Clover L, Saiz A et al. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol 2003; 54: 530-533.
28. Buckley C, Oger J, Clover L et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001; 50:73-78.
29. Liguori R, Vincent A, Clover L et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001; 124:2417-2426.
30. Bataller L, Dalmau J. Clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic disorders. Hematol Oncol Clin North Am 2006; 20:1319-1335.
31. Peterson K, Rosenblum MK, Kotanides H et al. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42:1931-1937.
32. Shams'ili S, Grefkens J, De Leeuw B et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126: 1409-1418.
33. Mason WP, Graus F, Lang B et al. Small cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997; 120:1279-1300.
34. Graus F, Keime-Guibert F, Rene R et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124:1138-1148.
35. Rojas-Marcos I, Rousseau A, Keime-Guibert F et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) 2003; 82:216-223.
36. Bernal F, Shams'ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60:230-234.
37. Luque FA, Furneaux HM, Ferziger R et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991; 29:241-251.
38. Sutton IJ, Barnett MH, Watson JD et al. Paraneoplastic brainstem encephalitis and anti-Ri antibodies. J Neurol 2002; 249:1597-1598.
39. Dalmau J, Graus F, Rosenblum MK et al. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine (Baltimore) 1992; 71:59-72.
40. Sabater L, Bataller L, Carpentier AF et al. Protein kinase C gamma autoimmunity in paraneoplastic cerebellar degeneration and non-small cell lung cancer. J Neurol Neurosurg Psychiatry 2006; 77:1359-1362.
41. Graus F, Lang B, Pozo-Rosich P et al. P/Q-type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002; 59:764-766.
42. Henson RA, Hoffman HL, Urich H. Encephalomyelitis with carcinoma. Brain 1965; 88:449-464.
43. Verschuuren J, Chuang L, Rosenblum MK et al. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol (Berl) 1996; 91:519-525.
44. Rojas I, Graus F, Keime-Guibert F et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55:713-715.
45. Dropcho EJ, Kline LB, Riser J. Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus. Neurology 1993;43:207-211.
46. Graus F, Dalmau J, Valldeoriola F et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuro Immunol 1997; 74:55-61.
47. Forsyth PA, Dalmau J, Graus F et al. Motor neuron syndromes in cancer patients. Ann Neurol 1997; 41:722-730.
48. Dalmau J, Graus F, Rosenblum MK et al. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine 1992; 71:59-72.
49. Sillevis Smitt P, Grefkens J, De Leeuw B et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002; 249:745-753.
50. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998; 50:652-657.
51. Honnorat J, Antoine JC, Derrington E et al. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 1996; 61:270-278.
52. Dropcho EJ. Antiamphiphysin antibodies with small cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol 1996; 39:659-667.
53. Yu Z, Kryzer TJ, Griesmann GE et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49:146-154.
54. Vernino S, Tuite P, Adler CH et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002;51:625-630.
55. Rosenfeld MR, Eichen JG, Wade DF et al. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001; 50:339-348.
56. Matsumoto L, Yamamoto T, Higashihara M et al. Severe hypokinesis caused by paraneoplastic anti-Ma2 encephalitis associated with bilateral intratubular germ-cell neoplasia. Mov Disord, 2007;22:728-31.
57. Denny-Brown D. Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiatry 1948; 11:73-87.
58. Chalk CH, Windebank AJ, Kimmel DW et al. The distinctive clinical features of paraneoplastic sensory neuronopathy. Can J Neurol Sci 1992; 19:346-351.
59. Oh SJ, Gurtekin Y, Dropcho EJ et al. Anti-Hu antibody neuropathy: a clinical, electrophysiological, and pathological study. Clin Neurophysiol 2005; 116:28-34.
60. Camdessanche JP, Antoine JC, Honnorat J et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies: a clinical and electrophysiological study of 20 patients. Brain 2002; 125:166-175.
61. Wanschitz J, Hainfellner JA, Kristoferitsch W et al. Ganglionitis in paraneoplastic subacute sensory neuronopathy: a morphologic study. Neurology 1997; 49:1156-1159.
62. Oh SJ, Dropcho EJ, Claussen GC. Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature. Muscle Nerve 1997; 20:1576-1582.
63. Russo C, Cohn SL, Petruzzi MJ et al. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 1997; 28:284-288.
64. Pranzatelli MR, Tate ED, Dukart WS et al. Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. J Pediatr 2005; 147:372-378.
65. Pranzatelli MR, Tate ED, Travelstead AL et al. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome. Pediatrics 2005; 115:e115-e119.
66. Koh PS, Raffensperger JG, Berry S et al. Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr 1994; 125:712-716.
67. Anderson NE, Budde-Steffen C, Rosenblum MK et al. Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine (Baltimore) 1988; 67:100-109.
68. Bataller L, Graus F, Saiz A et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001; 124:437-443.
69. Batchelor TT, Platten M, Hochberg FH. Immunoadsorption therapy for paraneoplastic syndromes. J Neurooncol 1998; 40:131-136.
70. Moersch F, Woltman H. Progressive fluctuating muscular rigidity and spasm ("stiff-man syndrome"): report of a case and some observations in 13 other cases. Mayo Clin Proc 1956; 31:421-427.
71. Silverman IE. Paraneoplastic stiff-limb syndrome. J Neurol Neurosurg Psychiatry 1999; 67:126-127.
72. Brown P, Marsden CD. The stiff-man and stiff-man-plus syndromes. J Neurol 1999; 246:648-652.
73. Folli F, Solimena M, Cofiell R et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993; 328:546-551.
74. De Camilli P, Thomas A, Cofiell R et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of stiff-man syndrome with breast cancer. J Expt Med 1993; 178:2219-2223.
75. Solimena M, Folli F, Aparisi R et al. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990; 322:1555-1560.
76. Ishizawa K, Komori T, Okayama K et al. Large motor neuron involvement in Stiff-man syndrome: a qualitative and quantitative study. Acta Neuropathol (Bed) 1999; 97:63-70.
77. Saiz A, Minguez A, Graus F et al. Stiff-man syndrome with vacuolar degeneration of anterior horn motor neurons. J Neurol 1999; 246:858-860.
78. Warich-Kirches M, Von Bossanyi P, Treuheit T et al. Stiff-man syndrome: possible autoimmune etiology targeted against GABA-ergic cells. Clin Neuropathol 1997; 16:214-219.
79. Dalakas MC, Fujii M, Li M et al. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001; 345: 1870-1876.
80. Ishii A, Hayashi A, Ohkoshi N et al. Progressive encephalomyelitis with rigidity associated with anti-amphiphysin antibodies. J Neurol Neurosurg Psychiatry 2004; 75:661-662.
81. Casado JL, Gil-Peralta A, Graus F et al. Anti-Ri antibodies associated with opsoclonus and progressive encephalomyelitis with rigidity. Neurology 1994; 44:1521-1522.
82. Barron KD, Rodichok LD. Cancer and disorders of motor neurons. In: Rowland LP, (ed.). Human Motor Neuron Diseases. New York: Raven Press, 1982:267-272.
83. Rosenfeld MR, Posner JB. Paraneoplastic motor neuron disease. In: Rowland LP, (ed.). Advances in Neurology, Volume 56: Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases. New York: Raven Press, 1991:445-59.
84. Forman D, Rae-Grant AD, Matchett SC et al. A reversible cause of hypercapnic respiratory failure: lower motor neuronopathy associated with renal cell carcinoma. Chest 1999; 115:899-901.
85. Younger DS, Rowland LP, Latov N et al. Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syndromes. Neurology 1990; 40:595-599.
86. Younger DS, Rowland LP, Latov N et al. Lymphoma, motor neuron diseases, and amyotrophic lateral sclerosis. Ann Neurol 1991; 29:78-86.
87. Croft PB, Urich H, Wilkinson M. Peripheral neuropathy of sensorimotor type associated with malignant disease. Brain 1967; 90:31-66.
88. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-1571.
89. Antoine JC, Mosnier JF, Absi L et al. Carcinoma-associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry 1999; 67:7-14.
90. Oh SJ. Paraneoplastic vasculitis of the peripheral nervous system. Neurol Clin 1997; 15:849-863.
91. Matsumuro K, Izumo S, Umehara F et al. Paraneoplastic vasculitic neuropathy: immunohistochemical studies on a biopsied nerve and post-mortem examination. J Intern Med 1994; 236:225-230.
92. Vincent D, Dubas F, Hauw JJ et al. Nerve and muscle microvasculitis in peripheral neuropathy: a remote effect of cancer? J Neurol Neurosurg Psychiatry 1986; 49:1007-1010.
93. Walsh JC. The neuropathy of multiple myeloma: an electrophysiological and histological study. Arch Neurol 1971; 25:404-414.
94. Kelly JJ, Jr. Peripheral neuropathies associated with monoclonal proteins: a clinical review. Muscle Nerve 1985; 8:138-150.
95. Kelly JJ, Jr. The electrodiagnostic findings in peripheral neuropathy associated with monoclonal gammopathy. Muscle Nerve 1983; 6:504-509.
96. Kelly JJ, Jr., Kyle RA, Miles JM et al. Osteosclerotic myeloma and peripheral neuropathy. Neurology 1983; 33:202-210.
97. Dispenzieri A, Kyle RA, Lacy MQ et al. POEMS syndrome: definitions and long-term outcome. Blood 2003; 101:2496-2506.
98. Dispenzieri A, Moreno-Aspitia A, Suarez GA et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 2004; 104:3400-3407.
99. Levine T, Pestronk A, Florence J et al. Peripheral neuropathies in Waldenstrom's macroglobulinaemia. J Neurol Neurosurg Psychiatry 2006; 77:224-228.
100. Dimopoulos MA, Panayiotidis P, Moulopoulos LA et al. Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000; 18:214-226.
101. Vital C, Vallat JM, Deminiere C et al. Peripheral nerve damage during multiple myeloma and Waldenstrom's macroglobulinemia: an ultrastructural and immunopathologic study. Cancer 1982; 50:1491-1497.
102. Pestronk A, Florence J, Miller T et al. Treatment of IgM antibody-associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003; 74:485-489.
103. Latov N. Prognosis of neuropathy with monoclonal gammopathy. Muscle Nerve 2000; 23:150-152.
104. Weide R, Heymanns J, Koppler H. The polyneuropathy associated with Waldenstrom's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab. Br J Haematol 2000; 109:838-841.
105. Isaacs H. A syndrome of continuous muscle-fibre activity. J Neurol Neurosurg Psychiatry 1961; 24:319-325.
106. Hart IK, Maddison P, Newsom-Davis J et al. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 2002; 125:1887-1895.
107. Newsom-Davis J, Mills KR. Immunological associations of acquired neuromyotonia (Isaac's syndrome): report of five cases and literature review. Brain 1993; 116:453-469.
108. Shillito P, Molenaar PC, Vincent A et al. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol 1995; 38:714-722.
109. Sinha S, Newsom-Davis J, Mills K et al. Autoimmune aetiology for acquired neuromyotonia (Isaac's syndrome). Lancet 1991; 338:75-77.
110. Hart IK, Waters C, Vincent A et al. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 1997;41:238-246.
111. van den Berg JS, Van Engelen BG, Boerman RH et al. Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous human immunoglobulin. J Neurol 1999; 246:623-625.
112. Chiappa KH, Young RR. A case of paracarcinomatous pandyautonomia. Neurology 1973; 23:423.
113. Fagius J, Westerberg C-E, Olsson Y. Acute pandysautonomia and severe sensory deficit with poor clinical recovery: a clinical, neurophysiological and pathological case study. J Neurol Neurosurg Psychiatry 1983; 46:725-733.
114. Lennon VA, Sas DF, Busk MF et al. Enteric neuronal autoantibodies in pseudoobstruction with small cell lung carcinoma. Gastroenterology 1991; 100:137-142.
115. Condom E, Vidal A, Rota R et al. Paraneoplastic intestinal pseudo-obstruction associated with high titres of Hu autoantibodies. Virchows Archiv A Pathol Anat 1993; 423:507-511.
116. Vernino S, Adamski J, Kryzer TJ et al. Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology 1998; 50:1806-1813.
117. Schroeder C, Vernino S, Birkenfeld AL et al. Plasma exchange for primary autoimmune autonomic failure. N Engl J Med 2005; 353:1585-1590.
118. Elmqvist D, Lambert EH. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin Proc 1968; 43:689-713.
119. O'Suilleabhain P, Low PA, Lennon VA. Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology 1998; 50:88-93.
120. Clark CV, Newsom-Davis J, Sanders MD. Ocular autonomic nerve function in Lambert-Eaton myasthenic syndrome. Eye 1990; 4:473-181.
121. Clouston PD, Saper CB, Arbizu T et al. Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurology 1992; 42:1944-1950.
122. Voltz R, Carpentier AF, Rosenfeld MR et al. P/Q-type voltage-gated calcium channel antibodies in patients with paraneoplastic disorders of the central nervous system. Muscle Nerve 1999; 22:119-122.
123. Eaton LM, Lambert EH. Electromyography and electrical stimulation of nerves in diseases of the motor unit: observations on a myasthenic syndrome associated with malignant tumors. JAMA 1957; 163:1117-1124.
124. Jablecki C. Lambert-Eaton myasthenic syndrome. Muscle Nerve 1984; 7:250-257.
125. Sanders DB. Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies. Ann Neurol 1995; 37:S63-S73.
126. Lang B, Newsom-Davis J, Wray D et al. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981; 2:224-226.
127. Lang B, Newsom-Davis J, Peers C et al. The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse. J Physiol (Lond) 1987; 390:257-270.
128. Motomura M, Lang B, Johnston I et al. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 1997; 147:35-2.
129. Newsom-Davis J. A treatment algorithm for Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 1998; 841:817-822.
130. Oh SJ, Kim DS, Kwon KH et al. Wide spectrum of symptomatic treatment in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 1998; 841:827-831.
131. Rich MM, Teener JW, Bird SJ. Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin. Muscle and Nerve 1997; 20:614-615.
132. Bain PG, Motomura M, Newsom-Davis J et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996; 47:678-683.
133. Newsom-Davis J. Lambert-Eaton myasthenic syndrome. Rev Neurol (Paris) 2004; 160:177-180.
134. Vedeler CA, Antoine JC, Giometto B et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 2006; 13:682-690.
135. Sigurgeirsson B, Lindelof B, Edhag O et al. Risk of cancer in patients with dermatomyositis or polymyositis: a population-based study. N Engl J Med 1992; 326:363-367.
136. Maoz CR, Langevitz P, Livneh A et al. High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum 1998; 27:319-324.
137. Garcia VE, Gutierrez GJ, Blanco GA. Report of 8 cases of dermatomyositis: does association of this entity and neoplasms exist? Rev Clin Esp 1998; 198:217-220.
138. Maugars YM, Berthelot JM, Abbas AA et al. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 1996; 14:263-274.
139. Leow YH, Goh CL. Malignancy in adult dermatomyositis. Int J Dermatol 1997; 36:904-907.
140. Davis MD, Ahmed I. Ovarian malignancy in patients with dermatomyositis and polymyositis: a retrospective analysis of fourteen cases. J Am Acad Dermatol 1997; 37:730-733.
141. Mahe E, Descamps V, Burnouf M et al. A helpful clinical sign predictive of cancer in adult dermatomyositis: cutaneous necrosis. Arch Dermatol 2003; 139:539.
142. Hochberg MC, Feldman D, Stevens MB et al. Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol 1984; 11:663-665.
143. Lam WW, Chan H, Chan YL et al. MR imaging in amyopathic dermatomyositis. Acta Radiol 1999; 40:69-72.
144. Dalakas MC, Ilia I, Dambrosia JM et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329:1993-2000.
145. Amato AA, Barohn RJ. Idiopathic inflammatory myopathies. Neurol Clin 1997; 15:615-648.
146. Couriel DR, Beguelin GZ, Giralt S et al. Chronic graft versus host disease manifesting as polymyositis: an uncommon presentation. Bone Marrow Transplant 2002; 30:543-546.
147. Arin MJ, Scheid C, Hubel K et al. Chronic graft versus host disease with skin signs suggestive of dermatomyositis. Clin Exp Dermatol 2006;31:141-143.
148. Levin MI, Mozaffar T, Al Lozi MT et al. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 1998; 50:764-767.
149. Anderlini P, Buzaid AC, Legha SS. Acute rhabdomyolysis after concurrent administration of interleukin-2, interferon-alfa, and chemotherapy for metastatic melanoma. Cancer 1995; 76:678-679.
150. Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve and muscle. Muscle Nerve 2000; 23:1800-1818.